Compare DexCom, Inc. (DXCM) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Snap Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Snap Inc trades at $6.24 (market cap $9.83B). The key difference: DexCom, Inc. is far larger — about 3.2× Snap Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Snap Inc for 68 Days on average.
| DXCM | SNAP | |
|---|---|---|
Market Cap | $31.86B | $9.83B |
Volume | 3,607,070 | 28,532,342 |
Sector | Health | Media |
52-Week High | $92.34 | $9.09 |
52-Week Low | $54.84 | $3.93 |
Typical Hold Time | 62 Days | 68 Days |
Enterprise Value | $31.32B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Snap Inc. (SNAP) trades at $6.235, up 7.31% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. Revenue growth is steady, reaching $5.93B in 2025, though the company remains unprofitable with a net income margin of -4.9%. Recent news highlights AI and AR developments, including partnerships with NVIDIA and Salesforce for its SPECS glasses, driving positive sentiment despite regulatory pressures.
The stock presents a speculative opportunity with analyst consensus pointing to a $7.78 price target, but risks include persistent losses, high debt, and intense competition. Upside hinges on monetizing new AI/AR initiatives, while downside protection is limited by weak profitability and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
